RA Capital Nexus Fund II, L.P. (CIK 1825376) reported 19 SEC Form 4 insider transactions across 6 companies over the past 18 months (most recent 2026-06-12). Recent activity: Buy JANX (5,500 shares), Buy ABOS (35,500 shares), Buy ACRV (9,366 shares), Buy ACRV (3.9M shares), Buy ABOS (6.1M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Janux Therapeutics, Inc. (JANX) | Director | Buy | 5,500 | $0 |
| 2026-06-05 | Acumen Pharmaceuticals, Inc. (ABOS) | Director | Buy | 35,500 | $0 |
| 2026-05-20 | Acrivon Therapeutics, Inc. (ACRV) | Director | Buy | 9,366 | $0 |
| 2026-04-23 | Acrivon Therapeutics, Inc. (ACRV) | Director | Buy | 3.9M | $7.0M |
| 2026-03-18 | Acumen Pharmaceuticals, Inc. (ABOS) | Director | Buy | 6.1M | $20.0M |
| 2026-01-07 | Climb Bio, Inc. (CLYM) | Director | Buy | 7,111 | $24,888 |
| 2025-12-15 | Climb Bio, Inc. (CLYM) | Director | Sell | 20.4M | $0 |
| 2025-12-15 | Climb Bio, Inc. (CLYM) | Director | Buy | 213,099 | $464,556 |
| 2025-12-15 | Climb Bio, Inc. (CLYM) | Director | Buy | 101,462 | $290,181 |
| 2025-09-30 | PepGen Inc. (PEPG) | Director | Buy | 9.4M | $30.0M |
| 2025-06-13 | Janux Therapeutics, Inc. (JANX) | Director | Buy | 3,750 | $0 |
| 2025-06-05 | Acumen Pharmaceuticals, Inc. (ABOS) | Director | Buy | 12,800 | $0 |
| 2025-05-14 | Werewolf Therapeutics, Inc. (HOWL) | Director | Buy | 320,913 | $275,985 |
| 2025-05-14 | Werewolf Therapeutics, Inc. (HOWL) | Director | Buy | 52,974 | $51,915 |
| 2025-05-14 | Werewolf Therapeutics, Inc. (HOWL) | Director | Buy | 162,539 | $159,288 |
| 2025-03-07 | Janux Therapeutics, Inc. (JANX) | Director | Buy | 110,206 | $3.4M |
| 2025-03-07 | Janux Therapeutics, Inc. (JANX) | Director | Buy | 304,287 | $9.3M |
| 2025-03-07 | Janux Therapeutics, Inc. (JANX) | Director | Buy | 37,455 | $1.2M |
| 2025-03-07 | Janux Therapeutics, Inc. (JANX) | Director | Buy | 372,093 | $11.5M |
Source: SEC Form 4 filings · as of 2026-06-12